Valuation: Clarity Pharmaceuticals Ltd

Market Cap 880M 616M 535M 499M 458M 865M 58.73B 5.89B 2.31B 29.3B 2.31B 2.26B 96.99B P/E 2026 *
-8.02x
P/E 2027 * -7.38x
Enterprise Value 719M 504M 437M 408M 375M 707M 47.99B 4.81B 1.89B 23.94B 1.89B 1.85B 79.25B EV / Sales 2026 *
-
EV / Sales 2027 * 890x
Free-Float
79.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.42%
1 week+0.43%
Current month-0.42%
1 month+9.77%
3 months-18.62%
6 months-23.38%
Current year-30.18%
1 week 2.03
Extreme 2.03
2.44
1 month 2.03
Extreme 2.03
2.65
Current year 1.8
Extreme 1.8
4.26
1 year 1.8
Extreme 1.8
5.87
3 years 0.88
Extreme 0.88
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 10/10/2024
Chief Executive Officer - 31/12/2009
Director of Finance/CFO - 03/04/2022
Director TitleAgeSince
Chairman - 31/10/2013
Director/Board Member - 30/09/2010
Director/Board Member 72 28/03/2016
Date Insider Type Main position Quantity % Market Cap.
28/11/25 Free

Chief Operating Officer

199,909 0.0537%
28/11/25 Free

Chief Operating Officer

287,530 0.0773%
28/11/25 Free

Chairman

744,922 0.2003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.42%+0.43%-47.09%+166.67% 621M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+3.27%-14.06%-12.13% 22.91B
-0.15%-7.92%-9.42%+352.23% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-0.56%+47.77%+170.70% 13.33B
Average +1.00%-1.61%+30.24%+165.69% 23.45B
Weighted average by Cap. +0.14%-1.69%+31.51%+123.25%

Financials

2026 *2027 *
Net sales - 933K 653K 567K 529K 486K 917K 62.26M 6.24M 2.45M 31.06M 2.45M 2.4M 103M
Net income -108M -75.55M -65.63M -61.2M -56.2M -106M -7.2B -722M -283M -3.59B -284M -277M -11.89B -121M -84.63M -73.52M -68.56M -62.95M -119M -8.07B -808M -317M -4.02B -318M -311M -13.32B
Net Debt -161M -113M -97.89M -91.28M -83.82M -158M -10.74B -1.08B -422M -5.36B -423M -414M -17.73B -49.5M -34.64M -30.1M -28.07M -25.77M -48.66M -3.3B -331M -130M -1.65B -130M -127M -5.45B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
-
Date Price Change Volume
03/08/26 A$2.360 -0.42% 1,517,520
31/07/26 A$2.370 +12.86% 3,785,600
30/07/26 A$2.100 +0.48% 1,473,451
29/07/26 A$2.090 -1.42% 1,789,347
28/07/26 A$2.120 -4.93% 2,678,021
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.360AUD
Average target price
7.228AUD
Spread / Average Target
+206.25%

Annual profits - Rate of surprise